The company is focused on targeting fibrotic mediators that drive disease progression and potentially avoid the limitations of current approaches. Its portfolio comprises three novel targets that are readily detectible in blood and correlate to disease severity.

The $85 million series A financing, which was raised in March 2023, will support advancement of these antibody treatments, with two programs advancing into human studies in 2024.